DEPOK (eNBe Indonesia) - Pharmaceutical firm Kalbe Farma (KLBF) booked a net profit of Rp2.3 trillion in the first nine months (9M) to September of 2021, grew 9.5% y/y as sales rose 11/7% y/y to Rp19.1 trillion.
Cost of goods sold increased 16% y/y to Rp10.8 trillion, and then gross profit increased 6.4% to Rp8.28 trillion.
Prescription pharmaceuticals contributed Rp4.191 trillion (up 11.1%), consumer health division contributed Rp2.9 trillion, nutritionals Rp5.17 trillion, and distribution & logistics contributed Rp6.8 trillion.
The COVID-19 pandemic hit all business activities, reduced purchasing power, and high public consumption for healthcare products. KLBF consistently maintains a strong financial position.
At the end of September 2021, the Company had cash and cash equivalents of Rp5.65 trillion. Total liabilities and equity increased 9.1% to Rp24.2 trillion.
Seeing the condition of the COVID-19 pandemic, which probably will continue until the end of the year, the Company targets its full-year 2021 net sales growth of 5-6% with projected net profit growth of around 5%-6%.
The Company maintained a capital expenditure (capex) budget of Rp1.0 trillion, which will be used to expand production and distribution capacity.***
